Join to view full profile
333 Cottman AveSuite N713Philadelphia, PA 19111
Phone+1 215-728-6900
Fax+1 215-214-3779
Dr. Geynisman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Daniel Geynisman, MD is an oncologist based in Philadelphia, PA with a subspecialty in Genitourinary Oncology. He received his fellowship in Hematology and Medical Oncology from the University of Chicago and completed his residency in Internal Medicine at UPMC Medical Education, after graduating from the University of Pittsburgh School of Medicine. Dr. Geynisman is experienced in treating conditions such as adrenal neoplasms, urologic oncology, kidney cancer, bladder cancer, and testicular cancer. Furthermore, he has made significant contributions to the field with numerous published articles in esteemed medical publications. He has also carried out clinical trials, notably 'A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer.'
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2010 - 2013
UPMC Medical EducationResidency, Internal Medicine, 2006 - 2010
University of Pittsburgh School of MedicineClass of 2006
Certifications & Licensure
DE State Medical License 2024 - 2027
NJ State Medical License 2026 - 2027
PA State Medical License 2006 - 2026
IL State Medical License 2010 - 2014
American Board of Internal Medicine Medical Oncology
American Board of Medical OncologyMedical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Clinical Trials
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Start of enrollment: 2020 Dec 01
Publications & Presentations
PubMed
- Re: Perioperative Apalutamide in High-risk Localized Prostate Cancer.Gregory M Hemenway, Daniel M Geynisman
European Urology. 2026-10-03 - Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospecti...Petros Grivas, Piyush K Agarwal, Hikmat Al-Ahmadie, Terence Friedlander, Daniel M Geynisman
Targeted Oncology. 2026-10-02 - Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response.Joy Li, Jordan Fredette, Nagendra Dhanikonda, Miraan Jhaveri, Aangi Shah
Clinical Genitourinary Cancer. 2026-10-01
Press Mentions
Drug Holidays for Advanced Kidney Cancer a Consideration for Selected PatientsNovember 19th, 2025- Daniel Geynisman on a Risk-Adapted Approach for Bladder Preservation in MIBCFebruary 27th, 2025
- Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBCDecember 23rd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
